Biden To Give Away 10% Of US COVID-19 Vaccine Supply As He Mulls Call For Patent Waiver
Executive Summary
President Biden announced plans to increase vaccination in the US as members of Congress and industry press the administration to take steps to expand global access to COVID-19 vaccines. BIO proposes an alternative to the TRIPS waiver that would expedite export of raw materials and manufacturing supplies.
You may also be interested in...
Pfizer/BioNTech’s COVID-19 Vaccine Moves Into Adolescents; Adcomm To Weigh Broader Pediatric Issues
Emergency use authorization in 12-15 year-olds follows announcement of a June advisory committee meeting on pediatric data requirements, including the FDA’s criteria for younger children. Authorization for US adolescents has raised ethical questions about prioritizing this lower-risk group over hard-hit populations overseas.
As Natco Ups The Ante Lilly Readies Voluntary Licensing For Olumiant
Eli Lilly responds with baricitinib donation plan and efforts to sew up royalty free voluntary licenses with local Indian firms as challenger Natco seeks a compulsory license for its version of the JAK inhibitor, which it is ready to launch.
South Africa Ups The Ante On COVID-19 Vaccines IP Waiver
With the COVID-19 situation spiraling out of control in India, Brazil and other parts of the world, calls for the suspension of IP protections on coronavirus vaccines are growing louder. But the R&D based pharmaceutical industry insists a waiver is not the way forward.